Small molecule · Immune activation, directed at Toll-like receptor 7 (TLR7) and Toll-like receptor 8 (TLR8) · developed by Nektar Therapeutics
Resiquimod pegol is a TLR7/8 agonist attached to polyethylene glycol through a hydrolyzable glycine linker, given intratumorally. It binds and activates TLR7 and TLR8 on antigen-presenting cells such as dendritic cells, promoting immune responses against tumor-associated antigens. It is being studied in melanoma, Merkel cell carcinoma, triple negative breast cancer, head and neck squamous cell carcinoma, renal cell carcinoma, colorectal cancer, and sarcoma.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT03435640 | Phase 1/2 | Melanoma | Terminated | NKTR |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Colorectal CancerHead and Neck Squamous Cell CarcinomaMelanomaMerkel Cell CarcinomaRenal Cell CarcinomaSarcomaTriple Negative Breast Cancer
Updated Oct 25, 2026. Something wrong or missing? Report it on the NKTR page.
See NKTR's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
NKTR catalysts and pipeline →